Ultimovacs ASA (OSL: ULTI)
Norway
· Delayed Price · Currency is NOK 2.740
+0.035 (1.29%)
Aug 30, 2024, 4:25 PM CET
Ultimovacs ASA Company Description
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway.
Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase.
Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA
| Country | Norway |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Carlos de Sousa |
Contact Details
Address: Ullernchausséen 64 Oslo, 0379 Norway | |
| Phone | 47 41 38 00 80 |
| Website | ultimovacs.com |
Stock Details
| Ticker Symbol | ULTI |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010851603 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carlos de Sousa | Chief Executive Officer |
| Hans Vassgard Eid | Chief Financial Officer |
| Ingunn Hagen Westgaard Ph.D. | Head of Research |
| Audun Tornes | Chief Technology Officer |
| Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer |
| Oivind Foss Ph.D. | Head of Clinical Operations |
| Antonius Berkien | Chief Business Officer |
| Orla Mc Callion | Head of Regulatory Affairs and QA |
| Prof. Gustav Gaudernack Ph.D. | Chief Scientific Officer |
| Torill Trones | Head of Office |